tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Evaxion Biotech expands R&D pipeline with new vaccine program

Evaxion initiates work to develop a new preventive vaccine against Group A Streptococcus, a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis and less severe yet serious diseases like strep throat and scarlet fever. The new vaccine program, named EVX-B4, has been added to Evaxion’s research & development pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1